Table 2. Theoretical study: improvement in psychiatric illness after use of psilocybin meta-analysis of nine cross-sectional studies/randomized controlled trials.
Study | Events | Sample size | Outcome (es) | SE | Var | w | w*es | w*(es2) | w2 | wv | wv*es | wv*(es2) | wv2 |
Carhart-Harris et al. 2016 [26] | 19 | 20 | 0.95 | 0.22 | 0.05 | 21.05 | 20 | 19 | 443.21 | 7.99 | 7.60 | 7.22 | 63.96 |
Carhart-Harris et al. 2017 [17] | 19 | 19 | 1 | 0.23 | 0.05 | 19 | 19 | 19 | 361 | 7.68 | 7.68 | 7.68 | 59.10 |
Davis et al. 2021 [32] | 17 | 24 | 0.71 | 0.17 | 0.03 | 33.88 | 24 | 17 | 1148.01 | 9.34 | 6.62 | 4.69 | 87.26 |
Ross et al. 2016 [33] | 20.3 | 29 | 0.7 | 0.16 | 0.02 | 41.43 | 29 | 20.3 | 1716.32 | 9.84 | 6.88 | 4.82 | 96.73 |
Griffiths et al. 2016 [4] | 41 | 51 | 0.80 | 0.13 | 0.02 | 63.44 | 51 | 41 | 4024.51 | 10.72 | 8.62 | 6.93 | 114.88 |
Larsen et al. 2017 [6] | 2 | 12 | 0.17 | 0.12 | 0.01 | 72 | 12 | 2 | 5184 | 10.94 | 1.82 | 0.30 | 119.63 |
Johnson et al. 2014 [23] | 12 | 15 | 0.8 | 0.23 | 0.05 | 18.75 | 15 | 12 | 351.56 | 7.64 | 6.11 | 4.89 | 58.39 |
Mason et al. 2019 [11] | 50 | 50 | 1 | 0.14 | 0.02 | 50 | 50 | 50 | 2500 | 10.25 | 10.25 | 10.25 | 105.12 |
Stroud et al. 2018 [12] | 17 | 17 | 1 | 0.24 | 0.06 | 17 | 17 | 17 | 289 | 7.33 | 7.33 | 7.33 | 53.78 |
Sums | 336.55 | 237 | 197.3 | 16017.63 | 81.74 | 62.92 | 54.11 | 758.78 |